DK0654037T3 - Enantiomere anti-retrovirus-nukleotidanaloger - Google Patents
Enantiomere anti-retrovirus-nukleotidanalogerInfo
- Publication number
- DK0654037T3 DK0654037T3 DK93918659T DK93918659T DK0654037T3 DK 0654037 T3 DK0654037 T3 DK 0654037T3 DK 93918659 T DK93918659 T DK 93918659T DK 93918659 T DK93918659 T DK 93918659T DK 0654037 T3 DK0654037 T3 DK 0654037T3
- Authority
- DK
- Denmark
- Prior art keywords
- enantiomeric
- nucleotide analogues
- retroviral nucleotide
- compounds
- retroviral
- Prior art date
Links
- 230000000798 anti-retroviral effect Effects 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6521—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/925,610 US6057305A (en) | 1992-08-05 | 1992-08-05 | Antiretroviral enantiomeric nucleotide analogs |
| PCT/US1993/007360 WO1994003467A2 (en) | 1992-08-05 | 1993-08-04 | Antiretroviral enantiomeric nucleotide analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0654037T3 true DK0654037T3 (da) | 1999-11-01 |
Family
ID=25451994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93918659T DK0654037T3 (da) | 1992-08-05 | 1993-08-04 | Enantiomere anti-retrovirus-nukleotidanaloger |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6057305A (cs) |
| EP (2) | EP0654037B1 (cs) |
| JP (2) | JP4083691B2 (cs) |
| AT (1) | ATE179983T1 (cs) |
| CA (2) | CA2574904C (cs) |
| CZ (2) | CZ293533B6 (cs) |
| DE (1) | DE69324923T2 (cs) |
| DK (1) | DK0654037T3 (cs) |
| ES (1) | ES2131116T3 (cs) |
| GR (1) | GR3030754T3 (cs) |
| SG (1) | SG47761A1 (cs) |
| WO (1) | WO1994003467A2 (cs) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| AU690587B2 (en) * | 1993-09-17 | 1998-04-30 | Gilead Sciences, Inc. | Method for dosing therapeutic compounds |
| IT1270008B (it) * | 1994-09-23 | 1997-04-16 | Ist Superiore Sanita | Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids |
| US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| EP0832896A4 (en) * | 1995-06-15 | 1998-11-25 | Mitsubishi Chem Corp | NUCLEOTIDES DERIVED FROM PHOSPHONATES |
| US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
| ES2198003T3 (es) * | 1996-07-26 | 2004-01-16 | Gilead Sciences, Inc. | Analogos de nucleotidos. |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| PT998480E (pt) * | 1997-07-25 | 2003-03-31 | Gilead Sciences Inc | Composicao de analogos nucleotidicos e metodos de sintese |
| EP1243590B1 (en) * | 1997-07-25 | 2005-02-09 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| EP1004022A4 (en) | 1997-08-08 | 2000-10-25 | Newbiotics Inc | METHODS AND COMPOSITIONS TO OVERCOME RESISTANCE TO BIO- AND CHEMOTHERAPY |
| US7462605B2 (en) * | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| BR9907736A (pt) | 1998-01-23 | 2000-10-17 | Newbiotics Inc | Agentes terapêuticos catalisados por enzima |
| US7419968B1 (en) | 1999-07-22 | 2008-09-02 | Celmed Oncology (Usa), Inc. | Methods for treating therapy-resistant tumors |
| US6683061B1 (en) * | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| EP1248790A1 (en) * | 1999-12-17 | 2002-10-16 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| CZ304886B6 (cs) | 2000-07-21 | 2015-01-07 | Gilead Sciences, Inc. | Prekurzory léčiv na bázi fosfonátových analogů nukleotidů a způsoby jejich výběru a přípravy |
| EP1359921A4 (en) | 2001-01-19 | 2006-09-06 | Newbiotics Inc | METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES |
| PL207187B1 (pl) | 2001-06-29 | 2010-11-30 | Acad Of Science Czech Republic | Pochodne 6-[2-(fosfonometoksy) alkoksy] pirymidyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te pochodne oraz ich zastosowanie |
| WO2003028737A1 (en) * | 2001-08-30 | 2003-04-10 | Mitsubishi Pharma Corporation | Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon |
| US7388002B2 (en) * | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| EP1450809A4 (en) * | 2001-11-14 | 2006-07-19 | Biocryst Pharm Inc | NUCLEOSIDES, THEIR PREPARATION AND USE AS AN INHIBITORS OF RNA VIRUS POLYMERASES |
| EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| HRP20140379A2 (hr) * | 2003-01-14 | 2014-07-18 | Gilead Sciences, Inc. | Pripravci i metode za kombiniranu antivirusnu terapiju |
| DE602004031115D1 (de) | 2003-06-16 | 2011-03-03 | Acad Of Science Czech Republic | Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga |
| WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
| UA93354C2 (ru) * | 2004-07-09 | 2011-02-10 | Гилиад Сайенсиз, Инк. | Местный противовирусный препарат |
| US9512125B2 (en) * | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| WO2006066074A2 (en) | 2004-12-16 | 2006-06-22 | The Regents Of The University Of California | Lung-targeted drugs |
| US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
| CA2606399A1 (en) * | 2005-04-25 | 2006-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| NZ569349A (en) * | 2005-12-14 | 2012-01-12 | Cipla Ltd | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| ES2423010T3 (es) * | 2006-04-04 | 2013-09-17 | The Regents Of The University Of California | Derivados de pirazolopirimidina para su uso como antagonistas de cinasa |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| US20080318904A1 (en) * | 2007-06-20 | 2008-12-25 | Protia, Llc | Deuterium-enriched tenofovir |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| KR101660050B1 (ko) | 2008-01-04 | 2016-09-26 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| JP5547099B2 (ja) * | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| EP2307434B1 (en) * | 2008-07-02 | 2014-02-12 | IDENIX Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| NZ590258A (en) | 2008-07-08 | 2013-10-25 | Intellikine Llc | Kinase inhibitors and methods of use |
| US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
| CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| ES2551738T3 (es) | 2010-06-11 | 2015-11-23 | Gilead Sciences, Inc. | Formulaciones tópicas antivirales para la prevención de la transmisión del VHS-2 |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2012079035A1 (en) | 2010-12-10 | 2012-06-14 | Sigmapharm Laboratories, Llc | Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs |
| ZA201103820B (en) | 2010-12-13 | 2012-01-25 | Laurus Labs Private Ltd | Process for the preparation of tenofovir |
| NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| CN103491962B (zh) | 2011-02-23 | 2016-10-12 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| EP2691409B1 (en) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2697238B1 (en) * | 2011-04-08 | 2019-03-20 | Laurus Labs Limited | Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof |
| CN103917237A (zh) * | 2011-05-10 | 2014-07-09 | 阿拉塔纳医疗公司 | 用于治疗猫逆转录病毒感染的化合物 |
| CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX2014002542A (es) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos. |
| CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| EP2780348B1 (en) | 2011-11-16 | 2017-03-01 | Laurus Labs Private Limited | Process for the preparation of tenofovir |
| ES2734495T3 (es) | 2011-12-22 | 2019-12-10 | Geron Corp | Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
| PL2914296T5 (pl) | 2012-11-01 | 2022-01-17 | Infinity Pharmaceuticals, Inc. | Leczenie nowotworu z zastosowaniem modulatorów izoform kinazy PI3 |
| BR112015023705A8 (pt) | 2013-03-15 | 2020-03-17 | Univ California | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| CN104230934B (zh) * | 2013-06-08 | 2016-12-28 | 上海医药工业研究院 | 一种化合物及其制备方法和用途 |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PH12016500582B1 (en) | 2013-10-04 | 2023-06-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
| CN103641857B (zh) * | 2013-12-20 | 2016-08-24 | 石药集团中诺药业（石家庄）有限公司 | 一种替诺福韦新晶型及其制备方法 |
| TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| CN113616656B (zh) | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| HRP20220651T1 (hr) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nukleotidni analozi |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| LT3236972T (lt) | 2014-12-26 | 2021-11-10 | Emory University | Antivirusiniai n4-hidroksicitidino dariniai |
| JP6980649B2 (ja) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 |
| EP3350191B9 (en) | 2015-09-15 | 2021-12-22 | The Regents of the University of California | Nucleotide analogs |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| IL263680B1 (en) | 2016-06-24 | 2025-06-01 | Infinity Pharmaceuticals Inc | Pi3k inhibitors for use in combination with a second therapeutic agent in treating, managing, or preventing cancer |
| HRP20241620T1 (hr) | 2017-12-07 | 2025-01-31 | Emory University | N4-hidroksi-citidin i derivati i antivirusna uporaba s njima povezana |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN115677774B (zh) * | 2021-07-23 | 2025-04-22 | 上海医药工业研究院有限公司 | 膦酸酯衍生物及其制备方法和用途 |
| JP2025526212A (ja) | 2022-07-21 | 2025-08-13 | アンティバ バイオサイエンシズ インコーポレイテッド | Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB544419A (en) * | 1940-01-08 | 1942-04-13 | Union Special Machine Co | Improvements in or relating to sewing machines |
| GB1544419A (en) * | 1975-11-19 | 1979-04-19 | Science Union & Cie | Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them |
| US4221910A (en) * | 1978-09-15 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | 9-(Hydroxy alkyl)purines |
| CS233665B1 (en) * | 1983-01-06 | 1985-03-14 | Antonin Holy | Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene |
| DE3490262T1 (de) * | 1983-05-24 | 1985-11-28 | Sri International, Menlo Park, Calif. | Antivirus-Mittel |
| PT78769A (en) * | 1983-06-24 | 1984-07-01 | Merck & Co Inc | Process for preparing (s)-9-(2,3-dihydroxy-1-propoxymethyl)guanine and derivatives thereof useful as antiviral agents |
| US4556727A (en) * | 1984-07-18 | 1985-12-03 | University Patents, Inc. | Ferroelectric smectic liquid crystals |
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| CS263952B1 (en) * | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
| CS264222B1 (en) * | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| US4851387A (en) * | 1986-10-14 | 1989-07-25 | Banyu Pharmaceutical Co., Ltd. | 5-substituted amino-4-hydroxy-pentanoic acid derivatives and their use |
| US5650510A (en) * | 1986-11-18 | 1997-07-22 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives |
| NZ222553A (en) * | 1986-11-18 | 1991-07-26 | Bristol Myers Co | Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions |
| EP0292244B1 (en) * | 1987-05-18 | 1993-08-11 | Canon Kabushiki Kaisha | Polymeric liquid crystal composition and liquid crystal device |
| JP2580205B2 (ja) * | 1987-10-21 | 1997-02-12 | チッソ株式会社 | 光学活性−２−ビフェニリルピリジン類 |
| NO172846C (no) * | 1987-12-25 | 1993-09-15 | Daiichi Seiyaku Co | Fremgangsmaate for fremstilling av 7,8-dihalogen-3-metyl-2,3-dihydro-2m-benzoksazinderivater og propoksybenzenderivater for utoevelse av fremgangsmaaten. |
| US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| AU4376589A (en) * | 1988-11-07 | 1990-05-10 | Gist-Brocades N.V. | Optically active benzoxazines and benzothiazines |
| DE3906357A1 (de) * | 1989-03-01 | 1990-09-06 | Boehringer Mannheim Gmbh | Neue acyclische nucleosid-analoga, verfahren zu ihrer herstellung und verwendung dieser verbindungen als antivirale arzneimittel |
| ATE124050T1 (de) * | 1990-04-20 | 1995-07-15 | Acad Of Science Czech Republic | Chirale 2-(phosphonomethoxy)propyl-guanine als antivirale agentien. |
| US5302585A (en) * | 1990-04-20 | 1994-04-12 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents |
| SK280313B6 (sk) * | 1990-04-24 | 1999-11-08 | �Stav Organick� Chemie A Biochemie Av �R | N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov |
| CS387190A3 (en) * | 1990-08-06 | 1992-03-18 | Ustav Organicke Chemie A Bioch | (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof |
| AU653552B2 (en) * | 1990-08-10 | 1994-10-06 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Novel process for the preparation of nucleotides |
| ES2118069T3 (es) * | 1990-09-14 | 1998-09-16 | Acad Of Science Czech Republic | Profarmacos de fosfonatos. |
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| WO1995032983A1 (en) * | 1994-05-31 | 1995-12-07 | Medivir Ab | Post exposure prevention of hiv |
-
1992
- 1992-08-05 US US07/925,610 patent/US6057305A/en not_active Expired - Lifetime
-
1993
- 1993-08-04 ES ES93918659T patent/ES2131116T3/es not_active Expired - Lifetime
- 1993-08-04 AT AT93918659T patent/ATE179983T1/de active
- 1993-08-04 EP EP93918659A patent/EP0654037B1/en not_active Expired - Lifetime
- 1993-08-04 CZ CZ2001529A patent/CZ293533B6/cs not_active IP Right Cessation
- 1993-08-04 EP EP98119443A patent/EP0897917A1/en not_active Withdrawn
- 1993-08-04 WO PCT/US1993/007360 patent/WO1994003467A2/en active IP Right Grant
- 1993-08-04 CA CA002574904A patent/CA2574904C/en not_active Expired - Lifetime
- 1993-08-04 SG SG1996004260A patent/SG47761A1/en unknown
- 1993-08-04 CZ CZ1995272A patent/CZ290797B6/cs not_active IP Right Cessation
- 1993-08-04 US US08/379,551 patent/US6653296B1/en not_active Expired - Lifetime
- 1993-08-04 DK DK93918659T patent/DK0654037T3/da active
- 1993-08-04 DE DE69324923T patent/DE69324923T2/de not_active Expired - Lifetime
- 1993-08-04 CA CA002141589A patent/CA2141589C/en not_active Expired - Lifetime
-
1999
- 1999-07-14 GR GR990401839T patent/GR3030754T3/el unknown
-
2000
- 2000-02-08 US US09/500,148 patent/US6479673B1/en not_active Expired - Fee Related
-
2004
- 2004-02-05 JP JP2004029994A patent/JP4083691B2/ja not_active Expired - Lifetime
-
2007
- 2007-12-18 JP JP2007326607A patent/JP2008120820A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0654037B1 (en) | 1999-05-12 |
| DE69324923D1 (de) | 1999-06-17 |
| ATE179983T1 (de) | 1999-05-15 |
| CA2141589C (en) | 2007-04-17 |
| JP2008120820A (ja) | 2008-05-29 |
| GR3030754T3 (en) | 1999-11-30 |
| CZ27295A3 (en) | 1995-12-13 |
| CA2141589A1 (en) | 1994-02-17 |
| JP2004189750A (ja) | 2004-07-08 |
| US6653296B1 (en) | 2003-11-25 |
| JP4083691B2 (ja) | 2008-04-30 |
| CA2574904A1 (en) | 1994-02-17 |
| CZ290797B6 (cs) | 2002-10-16 |
| EP0897917A1 (en) | 1999-02-24 |
| SG47761A1 (en) | 1998-04-17 |
| JPH08503927A (ja) | 1996-04-30 |
| WO1994003467A3 (en) | 1994-06-23 |
| US6479673B1 (en) | 2002-11-12 |
| US6057305A (en) | 2000-05-02 |
| JP3561272B2 (ja) | 2004-09-02 |
| ES2131116T3 (es) | 1999-07-16 |
| CZ293533B6 (cs) | 2004-05-12 |
| WO1994003467A2 (en) | 1994-02-17 |
| DE69324923T2 (de) | 1999-11-25 |
| EP0654037A1 (en) | 1995-05-24 |
| CA2574904C (en) | 2009-06-16 |
| HK1011998A1 (en) | 1999-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0654037T3 (da) | Enantiomere anti-retrovirus-nukleotidanaloger | |
| ATE108452T1 (de) | Puringruppen enthaltende cyclobutane. | |
| DE69001187D1 (de) | 6-epifumagillole, ihre herstellung und ihre verwendung. | |
| GR3017812T3 (en) | 2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof. | |
| NL300241I1 (nl) | Hydroxymethyl(methyleencyclopentyl)uurines en -pyrimidines. | |
| SE8500307D0 (sv) | Nya, antiviruella medel | |
| DE3851179D1 (de) | Oxetanocin. | |
| ES2131730T3 (es) | Preparacion de compuestos de guanina n-9 sustituidos. | |
| ES2108016T3 (es) | Triazolopiridazinas substituidas. | |
| ES2055211T3 (es) | Purinil- y pirimidinil-tetrahidrofuranos. | |
| DE68909143D1 (de) | Prostaglandin-Vorläufer und ihre Herstellung. | |
| DE69601451D1 (de) | UCK14-Verbindungen | |
| DK0439058T3 (da) | Acycliske terpener | |
| DK0717731T3 (da) | Antivirale difluorstatonanaloge | |
| ATE53029T1 (de) | Phenylharnstoff-herbicide. |